Table 1.

Distribution of pro-left ventricular hypertrophy (LVH) genotypes in patients with hypertrophic cardiomyopathy (HCM) and controls

	ACE	AGT	AGTR1	CMA	CYP11B2
HCM (n=26)
	II=6	CC=6	CC=1	AA=6	CC=4
	ID=14	TC=17	AC=10	GG=13	TC=14
	DD=6	TT=3	AA=15	AG=7	TT=8
Allele frequency	I=0.5	C=0.54	C=0.22	A=0.46	C=0.41
Prevalence of pro-LVH genotype	D=0.5	T=0.46	A=0.78	G=0.54	T=0.59
	DD=23%	CC=23%	CC=4%	AA=23%	CC=15%
Control (n=100)
	II=28	CC=17	CC=9	AA=23	CC=23
	ID=43	TC=58	AC=34	GG=58	TC=40
	DD=29	TT=25	AA=57	AG=19	TT=37
Allele frequency	I=0.5	C=0.46	C=0.26	A=0.52	C=0.43
	D=0.5	T=0.54	A=0.74	G=0.48	T=0.57
Prevalence of pro-LVH genotype	DD=29%	CC=17%	CC=9%	AA=23%	CC=23%

ACE, angiotensin converting enzyme gene; AGT, angiotensinogen gene; AGTR1, angiotensin II receptor type 1 gene; CMA, chymase A gene; CYP11B2, aldosterone synthase gene.